Moleculin Biotech, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$25.1M | -$26.6M | -$29.6M | -$30.6M | -$23.0M |
| Operating expenses | $25.1M | $26.6M | $29.6M | $30.6M | $23.0M |
| Cash from operations | -$22.7M | -$23.9M | -$23.6M | -$27.6M | -$19.0M |
| Capital expenditure | $0 | $13,000 | $124,000 | $67,000 | $19,000 |
| Free cash flow | -$22.7M | -$23.9M | -$23.7M | -$27.7M | -$19.0M |
| Total assets | $22.1M | $16.9M | $38.2M | $57.4M | $84.1M |
| Total liabilities | $7.1M | $5.7M | $12.1M | $5.2M | $5.1M |
Shares outstanding 5.3M · Free float 99.0%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.